Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...
Indianapolis-based Eli Lilly's expansion into Bristol will focus on manufacturing injectable medications, device assembly and ...
Eli Lilly (LLY) announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. Zepbound provided a 47% greater relative weight loss compared to Wegovy. On average ...
Given the strong demand expected for Eli Lilly's (NYSE:LLY) weight loss treatment Zepbound (tirzepatide) in the UK, the ...
Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and increased the price target ...
Eli Lilly And Co (NYSE:LLY) announced a $3 billion expansion of its Kenosha County, Wisconsin, manufacturing facility to ...
Eli Lilly & Co. is spending another $3 billion to build out its US manufacturing footprint as it ramps up production of its ...